Navigation Links
Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
Date:12/6/2011

ANAHEIM, Calif., Dec. 6, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ:   QCOR) announced today that executive management will present at the Oppenheimer Healthcare Conference to be held on December 13-14, 2011 in New York.  Don M. Bailey, President and Chief Executive Officer, is scheduled to present an overview of the Company on Tuesday, December 13, 2011 at 2:45 p.m. ET. 

A live webcast and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm.  The replay will be available for 90 days after the event.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product, Acthar, helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the use of Acthar to treat systemic lupus erythematosus, or SLE, for which Acthar is approved as both a maintenance therapy and to treat exacerbations.  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
2. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on June 9, 2011
3. Questcor Pharmaceuticals to Be Added to S&P SmallCap 600 Index
4. Questcor Announces Third Quarter 2010 Earnings Release Date and Conference Call
5. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. Access Pharmaceuticals Signs Agreement for CobaCyte® and CobOral® in RNAi Therapeutic Delivery
9. Radient Pharmaceuticals Announces Proxy Resolutions Approved at Special Meeting of Stockholders
10. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
11. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Mapp Biopharmaceutical,s valiant effort ... therapeutic to fight the Ebola outbreak will make ... the production of pharmaceuticals can be, according to ... that while some may be taken aback by ... with industry knowledge are well aware of the ...
(Date:10/20/2014)... 20, 2014 , A major ... and the delivery of care has revealed changing trends ... inequalities in the provision of healthcare services across the ... by United European Gastroenterology (UEG), have been announced today ... awareness of the burden of GI disorders across ...
(Date:10/20/2014)... Earle Martin , Chief Executive ... Ellen Teplitzky, an experienced attorney specializing in business ... has joined the firm as Director of Legal ... NDA Partners provides legal services, including research, ... top law firms and their clients in cases ...
(Date:10/19/2014)... Mass. , Oct. 19, 2014 NextCODE Health, ... the whole genome in real time, today announced the launch ... NextCODE Exchange , at the American Society of Human ... . To learn more, sign up and apply for free ... its unique features and benefits can be viewed here ...
Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3
... 27 Carna Biosciences, Inc. ("Carna"),announced on October ... with,Shanghai Universal Biotech Company ("SUBC"). Under the terms ... of Carna,s Protein,Kinases within China., With China,s ... life sciences, major biopharmaceutical companies have now established,research ...
... 27 BioAtom Inc. (private) announced,today that it will ... October 28, 2008 at 2:30 PM PDT (5:30 PM ... California., Myron Karasik, M.B.A., C.M.C., Director of Finance, ... of Costa Mesa, CA, dedicated,to development and commercialization of ...
... CITY, Oct. 24 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: ... company focused on,endocrine therapy and oncology, today announced ... Market, notifying AEterna Zentaris that during the 30,consecutive ... bid price of the,Company,s common shares had closed ...
Cached Biology Technology:Carna Biosciences Signs Distribution Agreement with Shanghai Universal Biotech Company 2BioAtom Inc. To Present at BIOCOM Investor Conference 2008 2AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price 2AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price 3
(Date:10/15/2014)... , Oct. 15, 2014 Sandata Technologies, ... home and community-based care, today announced it released ... Sandata,s Santrax® Electronic Visit Verification™ Solution (EVV™)  for ... a home health company founded in 1996 and ... . The study details the ...
(Date:10/15/2014)... Researchers have linked increased resistance to bacterial pneumonia in ... sex hormone estrogen. , Females are naturally more resistant ... of scientists has shown that increased resistance to bacterial ... nitric oxide synthase 3 (NOS3). They also show that ... the female sex hormone estrogen. , The team, lead ...
(Date:10/14/2014)... Research shows SIRT6—a protein known to inhibit the ... of skin cancers by turning on an enzyme that ... , Previously considered protective, SIRT6 is part of a ... genomic stability and prevent some of the genetic flaws ... can lead to cancer. This study, in the journal,s ...
Breaking Biology News(10 mins):Sandata Announces Case Study with Quality Care Services, Inc. 2Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
... global warming is causing the worldwide declines of amphibians ... to biologists. The findings, which contradict two widely held ... and toads and aid in their conservation. "We ... extinction event," said Peter Hudson, the Willaman professor of ...
... Greenland,s ice sheet Studies have indicated that ... increasing average summer air temperatures in southern coastal regions. ... mass from 1958 through 2008, Rignot et al. study ... sensing techniques; and surface mass balance, which is derived ...
... of DNA sequence information resulting from deciphering the human ... technological developments that have been vital in the identification ... for the development of novel genetic therapies to treat ... new genomic era heralds earlier diagnoses, greatly improved prevention ...
Cached Biology News:Global warming link to amphibian declines in doubt 2Global warming link to amphibian declines in doubt 3AGU journal highlights: Nov. 11, 2008 2AGU journal highlights: Nov. 11, 2008 3AGU journal highlights: Nov. 11, 2008 4AGU journal highlights: Nov. 11, 2008 5AGU journal highlights: Nov. 11, 2008 6AGU journal highlights: Nov. 11, 2008 7AGU journal highlights: Nov. 11, 2008 8AGU journal highlights: Nov. 11, 2008 9AGU journal highlights: Nov. 11, 2008 10Personalized medicine: Innovative online journal leads the way 2
Packaging: package with 500 l Patent/trademark/license (electronic): (r) Registered trademark of Molecular Probes...
... Rotofor purification system, 100-120 V, is used ... isoelectric focusing (IEF). The system includes both ... ml) focusing chambers, chassis, harvesting apparatus, cooling ... (pH 3-10), 60 ml syringe, colored protein ...
...
... B-Phycoerythrin Labeling Kit - NH2 is primarily ... for immunostaining and cellular proteins for tracing. ... has succinimidyl group (NHS), and can easily ... of IgG or other proteins without any ...
Biology Products: